- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06429176
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients With Cystic Fibrosis
A Phase 2a, Randomized, Placebo-Controlled, Double Blind Multiple Ascending Dose Study in Patients With Cystic Fibrosis Carrying the 3849 +10 Kb C->T Mutation to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84
The goal of this clinical trial is to learn if drug SPL84 is safe for adult patients with cystic fibrosis (CF). It will also learn if the drug works to treat works to treat CF with a specific mutation.
The purpose of this research study is to:
- test the safety and effectiveness of multiple doses of the study drug, SPL84
- test how multiple doses of the drug are processed by the body
Researchers will compare drug SPL84 to a placebo (a look-alike substance that contains no drug) to see if drug SPL84 is safe and if it works to treat CF.
Participants will:
Take drug SPL84 or a placebo by inhalation every week for 9 weeks months Visit the clinic approximately 14 times over 17.5 weeks for checkups and tests
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- Recruiting
- University of Alabama at Birmingham
-
Contact:
- Kathryn Monroe
- Phone Number: 205-638-5599
- Email: kathrynmonroe@uabmc.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of CF and two CF causing mutations; 3849+10 Kb C->T mutation on one allele in the CF transmembrane conductance regulator (CFTR) gene (homozygote or compound heterozygote). Source documentation from a certified genetic laboratory is required.
- Body mass index (BMI) of ≥ 17 kg/m2.
- FEV1 40-90% predicted at screening.
- Non-smokers or vapers for at least 180 days (6 months) prior to screening, per participant report.
Exclusion Criteria:
- Use of Kalydeco, Orkambi, Symdeko/Symkevi or Trikafta/Kaftrio within 30 days of first dose with study intervention.
- Use of any investigational drug (other than SPL84) or device within 30 days of first dose with study intervention.
- Use of systemic steroids over 3 consecutive months in the last 6 months prior to screening, or use of systemic steroids in the last month prior to screening. Use of inhaled steroids above 1 mg.
- Use of CF medications, e.g. inhaled antibiotics, dornase alfa (Pulmozyme), hypertonic saline and physiotherapy should be on stable regimen for the period 28 days prior to screening; those participants taking inhaled antibiotics for prophylaxis must be on a stable regimen of these drugs for at least 90 days prior to first dose with study intervention.
- Any acute infection including acute upper respiratory or lower respiratory infections, pulmonary exacerbation, changes in therapy for pulmonary disease, or any non CF-related illness which results in the initiation of any new therapy within 14 days prior to first dose with study intervention.
- Hemoptysis of greater than 30 mL within 90 days prior to Day 1, or hospitalization for hemoptysis within 6 months of first dose with study intervention.
- Liver disease characterized by clinically significant cirrhosis and/or documented portal hypertension.
- History of any organ transplantation.
- Documented coronavirus disease (COVID-19) infection within 4 weeks prior to dosing.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo solution for nebulization
|
Active Comparator: SPL84
|
SPL84 solution for nebulization
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and Tolerability of SPL84 as evaluated by number of subjects with at least one treatment-related adverse event (AE) or serious adverse event (SAEs)
Time Frame: Day 1 through Day 87
|
Incidence, nature, and severity of AEs and SAEs
|
Day 1 through Day 87
|
Safety and Tolerability of SPL84 as assessed by number of participants with abnormal heart rate
Time Frame: Day 1 through Day 87
|
Day 1 through Day 87
|
|
Safety and Tolerability of SPL84 as assessed by number of participants with abnormal respiratory rate
Time Frame: Day 1 through Day 87
|
Day 1 through Day 87
|
|
Safety and Tolerability of SPL84 as assessed by number of participants with abnormal systolic and diastolic blood pressure
Time Frame: Day 1 through Day 87
|
Day 1 through Day 87
|
|
Safety and Tolerability of SPL84 as assessed by number of participants with abnormal oximetry
Time Frame: Day 1 through Day 87
|
Day 1 through Day 87
|
|
Safety and Tolerability of SPL84 as assessed by number of participants with abnormal temperature
Time Frame: Day 1 through Day 87
|
Day 1 through Day 87
|
|
Safety and Tolerability of SPL84 as assessed by number of participants with abnormal hematology lab test results
Time Frame: Day 1 through Day 87
|
Day 1 through Day 87
|
|
Safety and Tolerability of SPL84 as assessed by number of participants with abnormal biochemistry lab test results
Time Frame: Day 1 through Day 87
|
Day 1 through Day 87
|
|
Safety and Tolerability of SPL84 as assessed by number of participants with abnormal urinalysis lab test results
Time Frame: Day 1 through Day 87
|
Day 1 through Day 87
|
|
Safety and Tolerability of SPL84 as assessed by number of participants with abnormal electrocardiogram (ECG) parameters
Time Frame: Day 1 through Day 87
|
using an ECG machine that automatically calculates heart rate and measure PR, QRS, QT, and QTc intervals
|
Day 1 through Day 87
|
Safety and Tolerability of SPL84 as assessed by number of participants with abnormal physical examination findings
Time Frame: Day 1 through Day 87
|
Complete physical examinations include general appearance, head, ears, eyes, nose, throat, thyroid, chest (heart, lungs), abdomen, skin, neurological, extremities, back, neck, musculoskeletal, and lymph nodes.
|
Day 1 through Day 87
|
Safety and Tolerability of SPL84 as assessed by number of participants with abnormal pulmonary function tests results
Time Frame: Day 1 through Day 87
|
Pulmonary function tests will be performed according to the American Thoracic Society (ATS)/European Respiratory Society (ERS) and forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and forced mid-expiratory flow (FEF25-75) will be measured
|
Day 1 through Day 87
|
Safety and Tolerability of SPL84 as assessed by number of participants with abnormal sputum microbiology results results
Time Frame: Day 1 through Day 87
|
Sputum microbiology will be performed with a microbiology based assay; organism growth will be identified.
|
Day 1 through Day 87
|
Safety and Tolerability of SPL84 as assessed by number of participants with abnormal immunogenicity results
Time Frame: Day 1 through Day 87
|
assessment of anti-SPL84 antibodies will be performed both in serum and sputum
|
Day 1 through Day 87
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Characterization of pharmacokinetics (PK) of SPL84: maximum serum concentration (Cmax)
Time Frame: Predose and 15 and 30 minutes and 1, 2, 4, 6, 8, and 24 hours postdose on Day 1 and Day 57; predose on Days 8 and 29; Days 64 and 87
|
Predose and 15 and 30 minutes and 1, 2, 4, 6, 8, and 24 hours postdose on Day 1 and Day 57; predose on Days 8 and 29; Days 64 and 87
|
|
Characterization of PK of SPL84: Time to Cmax (Tmax)
Time Frame: Predose and 15 and 30 minutes and 1, 2, 4, 6, 8, and 24 hours postdose on Day 1 and Day 57; predose on Days 8 and 29; Days 64 and 87
|
Predose and 15 and 30 minutes and 1, 2, 4, 6, 8, and 24 hours postdose on Day 1 and Day 57; predose on Days 8 and 29; Days 64 and 87
|
|
Characterization of PK of SPL84: terminal elimination half-life (t1/2)
Time Frame: Predose and 15 and 30 minutes and 1, 2, 4, 6, 8, and 24 hours postdose on Day 1 and Day 57; predose on Days 8 and 29; Days 64 and 87
|
Predose and 15 and 30 minutes and 1, 2, 4, 6, 8, and 24 hours postdose on Day 1 and Day 57; predose on Days 8 and 29; Days 64 and 87
|
|
Characterization of PK of SPL84: Area under the curve to the final sample (AUC0-t)
Time Frame: Predose and 15 and 30 minutes and 1, 2, 4, 6, 8, and 24 hours postdose on Day 1 and Day 57; predose on Days 8 and 29; Days 64 and 87
|
Predose and 15 and 30 minutes and 1, 2, 4, 6, 8, and 24 hours postdose on Day 1 and Day 57; predose on Days 8 and 29; Days 64 and 87
|
|
Characterization of PK of SPL84: Area under the curve to infinity (AUC0-∞)
Time Frame: Predose and 15 and 30 minutes and 1, 2, 4, 6, 8, and 24 hours postdose on Day 1 and Day 57; predose on Days 8 and 29; Days 64 and 87
|
Predose and 15 and 30 minutes and 1, 2, 4, 6, 8, and 24 hours postdose on Day 1 and Day 57; predose on Days 8 and 29; Days 64 and 87
|
|
Characterization of PK of SPL84: Apparent clearance (CL/F)
Time Frame: Predose and 15 and 30 minutes and 1, 2, 4, 6, 8, and 24 hours postdose on Day 1 and Day 57; predose on Days 8 and 29; Days 64 and 87
|
Predose and 15 and 30 minutes and 1, 2, 4, 6, 8, and 24 hours postdose on Day 1 and Day 57; predose on Days 8 and 29; Days 64 and 87
|
|
Characterization of excretion of SPL84: concentration of SPL84 in urine
Time Frame: Day 1 through Day 87
|
Day 1 through Day 87
|
|
Preliminary efficacy of SPL84 as assessed by change from baseline in percent predicted FEV1
Time Frame: Day 1 through Day 87
|
Pulmonary function tests will be performed according to the ATS/ERS
|
Day 1 through Day 87
|
Preliminary efficacy of SPL84 as assessed by change from baseline in Cystic Fibrosis Questionnaire-Revised Respiratory Symptom Score
Time Frame: Day 1 through Day 87
|
The score for is standardized on a 0- to 100-point scale on which higher scores represent a higher quality of life
|
Day 1 through Day 87
|
Preliminary efficacy of SPL84 as assessed by change from baseline in body weight
Time Frame: Day 1 through Day 87
|
Day 1 through Day 87
|
|
Preliminary efficacy of SPL84 as assessed by change from baseline of antibiotic treatment
Time Frame: Day 1 through Day 87
|
Day 1 through Day 87
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SPL84-002
- 2024-511184-28 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cystic Fibrosis
-
Hospital de Clinicas de Porto AlegreUnknownCystic Fibrosis | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in Children | Cystic Fibrosis With ExacerbationBrazil
-
University of Colorado, DenverCystic Fibrosis FoundationTerminatedCystic Fibrosis-related Diabetes | Cystic Fibrosis Pulmonary Exacerbation | Cystic Fibrosis in ChildrenUnited States
-
Royal College of Surgeons, IrelandThe Hospital for Sick Children; Imperial College London; Erasmus Medical Center; University College Dublin and other collaboratorsActive, not recruitingCystic Fibrosis | Adherence, Medication | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in Children | Cystic Fibrosis Liver DiseaseUnited Kingdom, Ireland
-
Herlev and Gentofte HospitalCopenhagen University Hospital, DenmarkActive, not recruitingMyocardial Infarction | Heart Diseases | Heart Failure | Stroke | Cystic Fibrosis | Heart Failure, Diastolic | Heart Failure, Systolic | Left Ventricular Dysfunction | Cystic Fibrosis-related Diabetes | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of Pancreas | Cystic Fibrosis, Pulmonary | Cystic...Denmark
-
The Hospital for Sick ChildrenCanadian Cystic Fibrosis FoundationActive, not recruitingCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis in ChildrenCanada
-
AzurRx SASCompletedCystic Fibrosis | Cystic Fibrosis Gastrointestinal Disease | Cystic Fibrosis of PancreasTurkey, Hungary
-
Dartmouth-Hitchcock Medical CenterTrustees of Dartmouth CollegeWithdrawnCystic Fibrosis-related Diabetes | Cystic Fibrosis Liver Disease | CF - Cystic FibrosisUnited States
-
Arrowhead PharmaceuticalsTerminatedCystic Fibrosis, PulmonaryAustralia, New Zealand
-
University of PortsmouthUniversity Hospital Southampton NHS Foundation Trust; Loughborough University; Queen Alexandra HospitalTerminated
-
University Hospital, BordeauxCompleted
Clinical Trials on SPL84
-
SpliSense Ltd.Completed